<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711890</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-18060</org_study_id>
    <secondary_id>NCI-2018-01534</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <nct_id>NCT03711890</nct_id>
  </id_info>
  <brief_title>Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer</brief_title>
  <official_title>Imaging and Detection of Micrometer Sized Early Stage Pancreatic Cancer by Using Endoscopic Ultra-High Resolution Optical Coherence Tomography (OCT) Using Resected Pancreatic Specimen, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well ultra-high resolution optical coherence tomography works in
      detecting micrometer sized early stage pancreatic cancer in participants with pancreatic
      cancer. Ultra-high resolution optical coherence tomography may help to accurately identify
      pancreatic cancer in resected pancreatic specimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the using of optical coherence tomography (OCT) to diagnose pancreatic cancer
      arising in the setting of intraductal papillary mucinous neoplasms (IPMN) using the resected
      pancreatic specimen.

      II. To correlate OCT imaging diagnosis with histologic findings in the human pancreatic duct.

      IPMN is a premalignant lesions arising in the pancreas. Typically, IPMNs are identified
      incidentally on imaging performed for other reason or related to vague abdominal pain or
      gastrointestinal complaints. In terms of IPMN, invasive cancer can be found in this setting
      between 20 to 50% of the time[7] Therefore, if a patient is diagnosed with IPMN, especially
      main duct type, the general recommendation is to undergo resection. We propose to assess the
      duct of the pancreatic specimen after resection to identify evidence of invasive malignancy
      by OCT imaging. Afterwards, the specimen will be undergoing histopathologic assessment using
      standard protocols. Our hypothesis is that OCT will accurately identify pancreatic cancer in
      resected pancreatic specimen. The assessment with OCT is non-invasive and will not harm to
      change the specimen prior to going to pathology for standard review. Future studies will then
      focus on using this imaging technique in vivo to endoscopically identify early stage
      pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will evaluate the accuracy of the optical coherence tomography (OCT) based diagnosis compare to the pathological diagnosis or the cancer cell derived exosomes test from the blood sample. Will compare the diagnosis results from the OCT imaging technology to standard histopathologic assessment and the blood test using 2-way tables. The agreement between two tests will be summarized with the overall agreement and the Cohen?s Kappa values.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type</condition>
  <arm_group>
    <arm_group_label>Diagnostic (resection, OCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Undergo OCT</description>
    <arm_group_label>Diagnostic (resection, OCT)</arm_group_label>
    <other_name>OCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo resection will be undertaken</description>
    <arm_group_label>Diagnostic (resection, OCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory Evaluation</intervention_name>
    <description>Labs will be obtained to test for cancer cell derived exosomes</description>
    <arm_group_label>Diagnostic (resection, OCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN

          -  Immediate surgery cohort: Informed consent will be obtained

          -  Adult patients undergoing pancreatic resection for a presumed IPMN

        Exclusion Criteria:

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Dillhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary E. Dillhoff, MD</last_name>
      <phone>614-293-7171</phone>
      <email>Mary.Dillhoff@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Mary E. Dillhoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamelinesline</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Mary Dillhoff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Intraductal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

